A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patil, Sunita Y.
- Adenoid Cystic Carcinoma of Parotid Gland: a FNAC Diagnosis
Authors
1 Dept of Pathology, J.N. Medical College, KLE University, Belgaum- 590010, Karnataka, IN
2 Department of Pathology, KLE University's J.N.Medical College, Belgaum, IN
3 Department of General Medicine, KLE University's, J.N.Medical College, Belgaum, IN
4 Department of Pathology, KLE University's J.N. Medical College, Belgaum, IN
Source
Indian Journal of Public Health Research & Development, Vol 4, No 1 (2013), Pagination: 194-196Abstract
Adenoid cystic carcinoma (ACC) is an uncommon salivary gland malignancy and accounts for 4% of all neoplasms of salivary glands. It most commonly occurs in minor salivary glands and palate, parotid being the least common site. It usually presents in 4th-6th decade with slight female predominance. ACC is an aggressive and recurrent tumor and has a poor prognosis with a 5 year survival rate of 60- 75%. However, prognosis is slightly favorable in parotid because of its accessibility. FNAC aids not only in the diagnosis but also in typing of ACC and hence in planning the surgical treatment. FNAC as a rapid and reliable diagnostic tool, aids in early diagnosis can help favor the prognosis.
Here we present a case of ACC in a 40 year old man, because of its rarity in parotid gland and early diagnosis on FNAC.
Keywords
Adenoid Cystic Carcinoma, Parotid Gland, FNAC
References
- Cheuk W, Chan J, Nagan R. Dedifferentiation in Adenoid Carcinoma of salivary glands. Am J Surg Pathol. 1999;23(4): 465-472.
- Partick JB. Adenoid cystic carcinoma of the head & neck: A review. Current opin tolaryngol Head Neck Surg. 2004;12: 127-132.
- Rosai J. Major & minor salivary glands. In: Rosai and Ackerman’s Surgical Pathology. 9th edition, vol1 Missouri;Mosby:2004: p873-916.
- Orell SR. Sterrette GF, Walters MN et al. Head and Neck; Salivary glands. In: Manual and atlas of the fine needle aspiration Cytology. 3rd edition. New York; Churchill Livingstone. 2001; p39-72.
- Lowhagan T. Tani EM, Skoog L. Salivary glands and rare head & neck Lesions. In: Bibbo M. Comprehensive cytopathology. 2nd edition. Philadelphia; W.B.Saunders company. 1997; p649-672.
- Expression of Perlecan (Heparan Sulphate Proteoglycan) in Oral Squamous Cell Carcinoma
Authors
1 Department of Oral Pathology, KLE VK Institute of Dental Sciences, Belgaum, IN
2 Department of Oral Pathology, ITS Dental College & Hospital, Noida, IN
3 Department of Pathology, JN Medical College, Belgaum, IN
4 Department of Public Health Dentistry, KLE VK Institute of Dental Sciences, Belgaum, IN
Source
Indian Journal of Public Health Research & Development, Vol 3, No 1 (2012), Pagination: 185-188Abstract
Background
Perlecan is a basement membrane heparan sulfate proteoglycan. It plays a vital role in cell- cell adhesion, cell-matrix adhesion and is associated with several growth factors. Recently its role has been found in many pathological and physiological conditions. Aim of this study was to understand the immunolocalisation of perlecan in normal mucosa and oral squamous cell carcinoma and also to derive a correlation between perlecan expression and various grades of carcinoma.
Method
A total of thirty tissue blocks comprising of ten normal mucosa and twenty oral squamous cell carcinoma were included in the study. They were examined for the presence of perlecan protein core by immunohistochemistry using monoclonal antibody (Anti-Basement Membrane-type heparan sulfate proteoglycan core protein. Specificity: Mouse monoclonal anti human Perlecan Clone No: 85-9). Interpretation of staining was done and the observations statisticaly analysed by Fisher exact tests to evaluate the expression of perlecan within and around the tumor islands.
Results
In normal epithelium perlecan expression was limited to basal layer. In oral squamous cell carcinoma, perlecan was present in surface epithelium, stroma as well as tumor islands. Perlecan expression within tumor islands became scarce with the higher grades of carcinoma.
Conclusions
It was deduced from the results that with the increase in degree of carcinoma; more heparanase enzyme acts on perlecan and from the breakdown of perlecan; fibroblast growth factor, transforming growth factor-β and other growth factors are released. All these factors are known to promote tumor growth.
Keywords
Perlecan, Immunohistochemistry, Heparan Sulphate Proteoglycan, Oral Cancer, Growth Factors, Squamous Cell CarcinomaReferences
- Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T. Intraepithelial expression of perlecan, a basement membrane type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 2004;33:87-95.
- Iozzo RV, Cohen IR, Grassel S, Murdoch AD. The Biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 1994;302:625-39.
- Ida-Yonemochi H, Ikarashi T, Nagata M, Hoshina H, Takagi R, Saku T. The basement membrane type heparan sulfate proteoglycan (perlecan) in ameloblastomas; its intercellular localization in stellate reticulum-like foci and biosynthesis by tumor cells in culture. Virchows Arch 2002;441:165-73.
- Ida-Yonemochi H, Ohshiro K, Swelam W, Metwaly H, Saku T. Perlecan, a basement membrane type heparan sulfate proteoglycan, in the enamel organ: its intraepithelial localization in the stellate reticulum. J Histochem and Cytochem 2005;53:763-72.
- Ida-Yonemochi H, Saku T. Perlecan, a heparan sulfate proteoglycan, is a major constituent of the intraepithelial stroma functioning in tooth morphogenesis. J Oral Biosc 2006;48:233-43.
- Tsuneki M, Cheng J, Maruyama S, Ida-Yonemochi H, Nakajima M, Saku T. Perlecan rich epithelial linings as a background of proliferative potentials of keratocystic odontogenic tumor. J Oral Pathol Med 2008;37:287-93.
- Murata M, Cheng J, Horino M, Hara K, Shimokawa H, Saku T. Enamel proteins and extracellular matrix molecules are colocalized in the pseudocystic stromal space of adenomatoid odontogenic tumor. J Oral Pathol Med 2000;29:483-90.
- White FH, Gohari K. Alterations in the volume of the intercellular space between epithelial cells of the hamster cheek-pouch: quantitative studies of normal and carcinogen –treated tissues. J Oral Pathol 1984;13:244-54.
- Saku T, Okabe H. Differential lectin bindings in normal and precancerous epithelium and squamous cell carcinoma of the oral mucosa. J Oral Pathol Med 1989;18:438-45.
- Wakulich C, Jackson-Boeters L, Daley TD, Wysocki GP. Immunohistochemical localization of growth factors fibroblast growth factor-1, fibroblast growth factor-2 and receptors for fibroblast growth factor -2 and fibroblast growth factor -3 in normal oral epithelium, epithelial dysplasias and squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 2002;93:573-9.
- Saku T, Shibata Y, Koyama Z, Cheng J, Okabe H, Yeh Y. Lectin histochemistry of cystic jaw lesions: an aid for differential diagnosis between cystic ameloblastoma and odontogenic cysts. J Oral Pathol Med 1991;20:108-13.
- Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis and angiogenesis. Cell 1994;79:1005-13.
- Mongiat M, Taylor K, Otto J, Aho S, Uitto J, Whitelock JM et al. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J Biol Chem 2000; 275:7095-100.
- Ohtani H, Nakumara S, Watanabe Y, Mizoi T, Saku T, Nagura H. Immunohistochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract. Laboratory Invest 1993; 68: 520-27.
- David G, Bai XM, Van Der Schueren B, Cassiman JJ, Van Den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol 1992;119:961-75.
- Jiang X, Multhaupt H, Chan E, Schaefer L, Schaefer RM, Couchman JR. Essential contribution of tumor derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem 2004;52:1575-90.
- Kimura S, Cheng J, Ida H, Hao N, Fujimori Y, Saku T. Perlecan (heparan sulphate proteoglycan) gene expression reflected in the characteristic histological architecture of salivary adenoid cystic carcinoma. Virchows Arch 2000;437:122-28.
- Mikami S, Ohashi K, Usui Y, Nemoto T, Katsube K, Yanagishita M et al. Loss of syndecan -1 and increased expression of heparanase in invasive esophageal carcinomas. Jpn J Cancer Res 2001;92:1062-73.